Saturday 17 October 2026
Export ZCMD’s income statement to Excel — free account
Zhongchao Inc.
ZCMD Healthcare Health Information Services
Zhongchao Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.4 million, down 28.3% from fiscal 2024.
1.29
0.10
−7.19%
Follow ZCMD
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 8,754.65 | 21,724.80 | 8,928.00 | 4,642.56 | 1,488.00 | 522.29 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 78,120.00 | 60,859.20 | 28,272.00 | 20,832.00 | 7,588.80 | 3,392.64 | |||||
| People | |||||||||||||||
| People | Employees | — | — | 90 | 91 | 88 | 136 | 109 | 142 | 111 | 33 | ||||
| Revenue/emp, $m | — | 0.00 | 0.14 | 0.16 | 0.20 | 0.12 | 0.13 | 0.14 | 0.14 | 0.34 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | 10 | 13 | 15 | 18 | 16 | 14 | 19 | 16 | 11 | ||||
| Gross margin, % | — | 59.56 | 65.36 | 68.72 | 65.99 | 57.92 | 44.92 | 43.80 | 56.18 | 45.02 | |||||
| EBT | — | 1 | 4 | 4 | 5 | 0 | (3) | (12) | 0 | (6) | |||||
| EBT margin, % | — | 13.66 | 27.23 | 29.48 | 27.47 | (0.68) | (18.02) | (61.63) | 0.39 | (50.71) | |||||
| Net income | — | 0 | 3 | 4 | 4 | 0 | (3) | (11) | 0 | (6) | |||||
| Depreciation | — | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | 0.39 | 4,594.96 | 5,132.00 | 5,451.45 | 4,793.18 | 4,043.29 | 5,552.54 | 2,266.40 | 309.10 | ||||
| Earnings | — | 0.06 | 1,074.18 | 1,411.91 | 1,337.60 | 74.31 | (817.42) | (3,232.52) | (89.17) | (171.84) | |||||
| Cash flow | — | (0.02) | 468.79 | 485.52 | (314.48) | 841.71 | (189.06) | 15.49 | (210.46) | 22.97 | |||||
| Capex | — | 0.00 | (388.07) | (452.72) | (48.67) | (529.38) | (143.86) | (230.89) | (435.03) | (4.15) | |||||
| Free cash flow | — | (0.02) | 80.71 | 32.79 | (363.15) | 312.32 | (332.91) | (215.40) | (645.49) | 18.83 | |||||
| Book value | — | 0.21 | 4,066.21 | 5,289.14 | 9,646.70 | 9,578.35 | 9,434.09 | 6,010.91 | 3,450.16 | 614.08 | |||||
| Shares, m | — | 25 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | 25.00 | 25.00 | 25.00 | 74,400.00 | 139,402.11 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| P/B | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| EV/Sales | — | 0.00 | 0.00 | 0.00 | (0.50) | (0.39) | (0.37) | (0.39) | (0.38) | (0.41) | |||||
| EV/FCF | — | 0.00 | 0.00 | 0.00 | 2.94 | 4.63 | 9.54 | 2.76 | 1.47 | 3.22 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | (1) | 1 | 1 | (1) | 3 | (1) | 0 | (1) | 1 | ||||
| Capex | — | 0 | (1) | (1) | 0 | (2) | (1) | (1) | (3) | 0 | |||||
| Free cash flow | — | (1) | 0 | 0 | (1) | 1 | (1) | (1) | (5) | 1 | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | 5 | 10 | 12 | 27 | 24 | 19 | 16 | 17 | 15 | ||||
| Total debt | — | — | 1 | 0 | 0 | 0 | 0 | — | — | — | |||||
| Net debt | — | (5) | (8) | (8) | (17) | (14) | (12) | (13) | (13) | (14) | |||||
| Shareholders’ equity | — | 5 | 11 | 15 | 32 | 33 | 33 | 21 | 24 | 23 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | 14.55 | 42.99 | 25.46 | 16.97 | 0.67 | (7.85) | (35.97) | (2.56) | (25.22) | ||||
| ROIC | — | 0.00 | 67.54 | 30.33 | 19.05 | (1.09) | (8.80) | (109.36) | (1.93) | (44.60) | |||||
| ROE | — | 18.40 | 36.39 | 30.29 | 18.90 | 0.74 | (8.97) | (41.94) | (2.85) | (27.00) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jan 0001
Charts ten years each
Zhongchao Inc. vs peers in Health Information Services (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| RNLXY Renalytix plc - Sponsored ADR | $17.2M | — (loss-making) | — | +13.73% (above 0%: growing) | n/m | +17.96% (above 0%: growing) | 19.16% | (783.91%) | Compare |
| BFRG Bullfrog AI Holdings Inc. | $9.9M | — (loss-making) | — | +2,054.00% (above 0%: growing) | n/m | −5.67% (below 0%: shrinking) | 49.63% | (658.82%) | Compare |
| ETAOF ETAO International Co., Ltd. | $9.8M | — (loss-making) | — | — | n/m | +37,595.70% (above 0%: growing) | — | 0.00% | Compare |
| HCTI Healthcare Triangle, Inc. | $7.4M | 0.0× | — (loss-making) | +158.38% (above 0%: growing) | n/m | +67.48% (above 0%: growing) | 22.48% | (44.28%) | Compare |
| MGRX Mangoceuticals, Inc. | $7.1M | — (loss-making) | — | −59.07% (below 0%: shrinking) | n/m | +79.27% (above 0%: growing) | 64.24% | (1,501.45%) | Compare |
| HLTHQ Cue Health Inc. | $6.9M | — (loss-making) | — (loss-making) | −87.19% (below 0%: shrinking) | n/m | +50.55% (above 0%: growing) | (90.14%) | (792.13%) | Compare |
| ZCMD Zhongchao Inc. | $6.2M | — (loss-making) | — | +20.44% (above 0%: growing) | −550.00% (below 0%: shrinking) | +191.85% (above 0%: growing) | 41.67% | 0.00% | |
| ACON Aclarion, Inc. | $5.6M | — (loss-making) | — (loss-making) | +30.57% (above 0%: growing) | n/m | −41.41% (below 0%: shrinking) | 32.94% | (11,506.75%) | Compare |
| VSEED VSee Health, Inc. | $2.8M | — (loss-making) | — (loss-making) | +48.02% (above 0%: growing) | n/m | −257.62% (below 0%: shrinking) | 13.20% | (172.69%) | Compare |
| Median of peers | $7.3M | — | — | +30.57% | — | +34.25% | 22.48% | (721.36%) |
Zhongchao Inc. (ZCMD) key facts
- Concern: Zhongchao Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.4 million, down 28.3% from fiscal 2024.
- Concern: Zhongchao Inc. reported a net loss of $5.8 million, or a loss of $171.84 per share, for fiscal 2025.
- Zhongchao Inc. (ZCMD) is a Health Information Services company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, ZCMD traded at $1.29, a market capitalization of $6.2 million.
- Return on equity was −27.0% and debt-to-equity 0.00.
- Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 9.11 (safe zone) for fiscal 2025.